HLA-DRA Protein (AA 25-216) (His tag)
-
- Target Alle HLA-DRA Proteine anzeigen
- HLA-DRA (HLA Class II DR alpha (HLA-DRA))
- Protein-Typ
- Recombinant
- Proteineigenschaft
- AA 25-216
-
Spezies
- Schwein
-
Quelle
- Escherichia coli (E. coli)
- Aufreinigungstag / Konjugat
- Dieses HLA-DRA Protein ist gelabelt mit His tag.
- Applikation
- SDS-PAGE (SDS), Western Blotting (WB), Immunogen (Imm), Positive Control (PC)
- Sequenz
- Val25-Thr216 (Accession # NM_001113706.1)
- Produktmerkmale
- Recombinant HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA), Prokaryotic expression, Val25-Thr216 (Accession # NM_001113706.1), N-terminal His Tag
- Reinheit
- > 95 %
- Top Product
- Discover our top product HLA-DRA Protein
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Isoelectric Point:5
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4, containing 0.01 % SKL, 1 mM DTT, 5 % Trehalose and Proclin300.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-80 °C
- Informationen zur Lagerung
- Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
- Haltbarkeit
- 12 months
-
- Target
- HLA-DRA (HLA Class II DR alpha (HLA-DRA))
- Andere Bezeichnung
- HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA Produkte)
- Synonyme
- HLA-DRA1 Protein, MLRW Protein, DR-alpha Protein, HLA-DRA Protein, Mamu-DRA1 Protein, major histocompatibility complex, class II, DR alpha L homeolog Protein, major histocompatibility complex, class II, DR alpha Protein, hla-dra.L Protein, HLA-DRA Protein, MAMU-DRA Protein, BOLA-DRA Protein
- Hintergrund
- MHCDRa, HLADRa, Major Histocompatibility Complex Class II DR Alpha
- NCBI Accession
- NM_001113706
- Pathways
- T-Zell Rezeptor Signalweg, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-